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Abstract
Dengue is a rapidly emerging, mosquito-borne viral infection, with an estimated 400 million 
infections occurring annually. To gain insight into dengue immunity, we characterized 145 human 
monoclonal antibodies (mAbs) and identified a previously unknown epitope, the envelope dimer 
epitope (EDE), that bridges two envelope protein subunits that make up the 90 repeating dimers 
on the mature virion. The mAbs to EDE were broadly reactive across the dengue serocomplex and 
fully neutralized virus produced in either insect cells or primary human cells, with 50% 
neutralization in the low picomolar range. Our results provide a path to a subunit vaccine against 
dengue virus and have implications for the design and monitoring of future vaccine trials in which 
the induction of antibody to the EDE should be prioritized.
Dengue is a mosquito-borne systemic viral infection caused by any of four antigenically 
related dengue viruses (serotypes DENV-1, DENV-2, DENV-3 and DENV-4)1, which differ 
by 30–35% in amino acid sequence. Infection with one serotype leads to lifelong protection 
against that serotype but not against the other serotypes. There are estimated to be 400 
million dengue infections annually, of which approximately one quarter are symptomatic2. 
Meanwhile, the geographical spread of DENV continues to widen, threatening the southern 
United States and Australia, and there is also concern about possible spread to southern 
Europe2. The more severe cases can develop dengue hemorrhagic fever, which can lead to 
shock, hemorrhage and death. The primary pathogenic lesion in dengue hemorrhagic fever is 
a profound vascular leak that occurs at the time of viral clearance, which has led some to 
suggest it is an immunopathology driven by T cells3,4.
There is epidemiological evidence that severe disease is more likely to occur during a 
secondary infection (with an unrelated serotype) than during the first or primary infection 
with DENV5. Antibody-dependent enhancement (ADE)6 has been proposed to explain the 
increase in severity seen on secondary infection. This hypothesis states that antibody 
generated against the primary infecting DENV serotype will not be of sufficient avidity or 
concentration to neutralize the secondary serotype but will still opsonize the virus6. 
Opsonized virus can then be targeted for Fc receptor–mediated uptake into monocytes or 
macrophages, which leads to enhanced infection and drives greater virus production.
The enhancement of disease upon secondary infection and the need to protect against four 
diverse serotypes sets a high bar for vaccines, which are urgently needed to protect against 
this rapidly emerging disease2. Most vaccines against DENV in development aim to raise 
virus-neutralizing antibodies, and the DENV envelope (E) protein, which coats the virus, is 
the main focus of this effort7. A trial of a tetravalent live attenuated vaccine against DENV 
resulted in an overall vaccine efficacy of 30.2% (confidence interval, 13.4–56.6), with 
almost no efficacy against DENV-2, despite its stimulating the production of antibodies with 
in vitro neutralizing activity against all four serotypes8. A second trial also showed poor 
efficacy against DENV-2 infection9. There is a pressing need to investigate the human 
antibody response to naturally acquired DENV infection, as well as after vaccination, to 
understand the correlates of protective immunity.
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The recognition of DENV particles by antibodies is complicated by several different 
compositions and conformations of the virus glycoprotein shell that are displayed at 
different phases of the virus life cycle10,11. The immature viral particle has a full 
complement of precursor membrane protein (prM) in a 1:1 association with E protein. In an 
environment of neutral pH, such as in the endoplasmic reticulum lumen in which the 
particles bud, the immature virion displays a characteristic appearance of 60 spikes, each a 
heterohexamer (usually referred to as a ‘trimer’) made up of three prM and three E 
proteins10-13. Exposure to low pH in the Golgi results in a transition at the virus surface in 
which trimers dissociate and the individual subunits reassociate as dimers, displaying a 
smooth herringbone lattice of 90 dimers of E protein (‘E dimers’). In these particles, prM is 
bound at the E-dimer interface, covering the fusion loop and exposing a cleavage site for the 
host protease furin, which resides in the trans-Golgi network. Following furin-mediated 
cleavage of prM, mature viral particles are released into the environment; these lose the 
precursor moiety of prM that results from cleavage by furin. The release of prM primes the 
particle to become infectious, reacting to the acidic pH of endosomes to induce fusion of 
viral and endosomal membranes14,15. An important and additional level of complexity is 
that the cleavage of prM is frequently incomplete, which leads to a population of partially 
mature viruses with varying degrees of cleavage16. Viruses containing large amounts of prM 
are not infectious, whereas viruses with lower levels of prM are still infectious; furthermore, 
it has been postulated that the noninfectious particles with large amounts of prM can be 
driven to infect by ADE17. Expansion of smooth mature particles into a bumpy form upon 
exposure to temperatures above 34 °C, in which the E dimers rearrange with respect to each 
other, has also been described for DENV-2 virions18,19.
Here we examined a large panel of human mAbs that target DENV E protein, which allowed 
us to delineate the antigenic landscape during natural dengue infection. We have identified a 
new class of highly potent and broadly reactive antibodies able to neutralize multiple DENV 
serotypes. Antibodies directed against the envelope dimer epitope (EDE) were the only class 
of antibody in this study able to neutralize DENV produced in primary human cells.
RESULTS
Generation of mAb to dengue
We used blood samples from seven hospitalized patients (Supplementary Table 1) to 
produce human mAbs that reacted to DENV E protein20,21. We sorted plasmablasts 
(CD3−CD20loCD19+ CD27hiCD38hi or CD3−CD20−CD19+CD27hiCD38hi) from peripheral 
blood and, by enzyme-linked immunospot assay, demonstrated that 50–90% of these cells 
secreted antibody to DENV (anti-DENV), consistent with reported frequencies22,23. We 
amplified sequences encoding heavy and light chains from single-cell cDNA and cloned 
these into expression vectors, and produced recombinant mAb via transfection into 293T 
human embryonic kidney cells. We produced 145 human mAbs; as shown by enzyme-linked 
immunosorbent assay (ELISA), 84% reacted to all four DENV serotypes, 13% reacted to 
two or three serotypes and only 3% reacted to a single serotype (Fig. 1a).
For the initial antibody screen, we used ELISA of captured whole virions from each of the 
four serotypes, rather than recombinant protein or fixed cells, to ensure we obtained a fully 
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representative panel of antibodies. Only 57% of the mAbs reacted to DENV E protein, as 
shown by immunoblot analysis (Fig. 1a). The mAbs that were not reactive by immunoblot 
analysis (IB−) also failed to react to recombinant E protein when assessed by ELISA (data 
not shown). This property allowed us to categorize the mAbs into two broad groups: those 
that were reactive by immunoblot analysis (IB+), and those that recognized only an epitope 
present on the intact virion that was IB−. Most of the IB+ mAbs were fully cross-reactive 
among the four virus serotypes, whereas among the IB− mAbs, 41 of 62 were fully cross-
reactive, with a further 17 of 62 reacting to DENV-1, DENV-2 and DENV-3 (Fig. 1b). 
These findings showed that the presence of a large group of antibodies that reacted to 
complex conformational epitopes on the DENV virion were produced as part of the human 
antibody response to natural infection with DENV.
Epitope mapping of anti-DENV
The mature DENV virion contains 180 E proteins that form 90 dimers, which are arranged 
through icosahedral symmetry to form a smooth glycoprotein shell24 (Supplementary Fig. 
1). To gain more insight into the epitopes recognized by the mAbs, we created 65 DENV 
virus-like particles (VLPs) that contained alanine substitutions at solvent-exposed residues 
predicted from available structural studies to be on the virion surface10,24,25. We captured 
VLPs onto ELISA plates coated with anti-prM and assessed reactivity to the panel of mAbs 
by ELISA. All VLPs contained similar amounts of prM, which was consistent with the 
relatively large prM content of virus produced in 293T cells and Vero African green monkey 
kidney cells (described in more detail below).
We screened the mutant VLPs against the 145 mAbs by ELISA17. We deemed relevant 
those substitutions that resulted in a reduction in antibody binding of >80%. For 
clarification, VLPs are not homogeneous in structure, and most are smaller in size than 
infectious DENV virions. The fraction of smallest radius has been characterized structurally 
and has been shown to be composed of 30 E dimers, which display an arrangement different 
from that of the 90 E dimers observed on infectious, mature tick-borne encephalitis 
virions26. The different packing of E dimers in the VLP might therefore disrupt some 
complex quaternary epitopes formed between adjacent dimers in the lattice of E proteins; 
fortunately, however, all mAbs in this study bound to the control, non-mutant VLP, which 
confirmed the utility of VLPs for mapping the epitopes of this antibody panel.
With the VLP panel, we assigned 112 of 145 mAbs an epitope on E protein to which they 
bound (Fig. 2a and Supplementary Table 2). Thirty-three mAbs, all of which reacted to E 
protein by immunoblot analysis, remained unmapped with the mutant VLP panel, which 
may have reflected the fact that a diffuse epitope relies on the sum of many interactions or 
that the change to alanine was too conservative to disrupt antibody binding. These mapping 
results delineated a previously unknown conformationally sensitive epitope for anti-DENV 
(described below).
mAbs to the fusion loop epitope
Studies of mouse mAbs raised against DENV have described a major class of antibodies that 
target the fusion loop epitope (FLE) centered on the hydrophobic fusion peptide on E 
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protein used by the virus to fuse viral and host cell membranes in the acidic endosomal 
environment. Trp101 has been shown to be a key residue for the binding of various mAbs to 
FLE27-31. Of the 83 mAbs that bound to the E protein, as assessed by immunoblot analysis, 
46 were sensitive to the substitution of Trp101 (Fig. 2a). Of those 46 FLE-specific mAbs, 40 
were sensitive to the substitution of Trp101 in isolation, whereas other mAbs were also 
sensitive to the substitution of Gly106 and Leu107 (data not shown).
A crystal structure of mAb E53 to FLE bound to E protein from West Nile virus has shown 
contacts with residues 104–110, but not Trp101, and with residues 74–79 in the BC loop, 
which lies near the fusion loop32. Only two of the FLE-specific mAbs described here were 
sensitive to changes in the BC loop; binding was lost when amino acids 76–79 were changed 
to alanine (data not shown), similar to 1C19, a published cross-reactive antibody to dengue 
that binds to the BC loop30.
Conformationally sensitive mAbs to DENV
We categorized the IB− mAbs into five distinct subgroups on the basis of their pattern of 
reactivity to the VLP mutants (Fig. 2a and Supplementary Table 2). Most IB− mAbs were 
sensitive to changes in fusion loop residue Trp101 (W101A) but are not to be confused with 
the classic, linear fusion loop–specific antibodies described above, as the epitope is much 
more extensive with additional determinants on domains I, II and III. Most of the IB− mAbs 
reacted to EDE, and we subcategorized these into two distinct subgroups: those that 
recognized E dimer–dependent epitope 1 (EDE1 mAbs), and those that recognized EDE2 
(EDE2 mAbs) (Fig. 2a and Supplementary Table 2). These two subgroups could be 
distinguished by sensitivity to changes at residues 153 and 155 in EDE2 that disrupt an N-
linked glycosylation site. Twelve mAbs constituted three further subgroups with different 
epitopes and function: IB–3 mAbs were similar to EDE1 mAbs but were also sensitive to 
changes at Leu107 and Lys295; IB–4 mAbs were not sensitive to changes at Trp101; and 
IB–5 mAbs constituted a group of five mAbs that bound to the fusion loop Trp101 only, but 
the epitope was recapitulated only on intact virions. The data from the alanine scan 
delineated two related groups of antibodies, EDE1 mAbs and EDE2 mAbs, with a 
previously undescribed mode of binding to the DENV virion.
mAbs to EDE bind across the E dimer interface
Mapping the alanine-scanning results onto the structure of a previously determined DENV-2 
E dimer25 indicated that EDE is a complex epitope that could be contained within an E 
dimer or could be shared by adjacent E dimers at the surface of the virion (Fig. 2b). We 
therefore analyzed DENV-2 particles in complex with the antigen-binding fragment (Fab) of 
one of the EDE2 mAbs (747(4)B7) by cryo electron microscopy (cryo-EM) and obtained a 
three-dimensional reconstruction at sub-nanometer resolution (Fig. 2c). The reconstruction 
showed density for bound Fab of mAb 747(4)B7 (Fab 747(4)B7), which indicated that it 
bound at an intradimer epitope and not across dimers. This was better demonstrated with the 
density corresponding to bound Fab over the underlying organization of the E dimers on the 
glycoprotein shell after superposition with the 3.5Å cryo-EM structure of DENV-2 (ref. 24), 
with three E polypeptides of the icosahedral asymmetric unit presented here in different 
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colors and as solid surfaces (Fig. 2d). The same superposition with the density map of the 
complex can also be presented as a transparent mesh (Supplementary Fig. 2).
The distribution of E and M subunits in a herringbone pattern was such that there were two 
different types of dimers: red-red dimers related by the icosahedral twofold axis, and cyan-
yellow dimers related by a local twofold axis (Fig. 2d). The Fab density on the E dimer was 
at the E dimer interface, over the fusion loop, and matched the clusters of mutations from 
the alanine scanning experiments (Fig. 2e). We extracted dimer from the cryo-EM structure 
of the virion–Fab 747(4)B7 complex and have presented it along the molecular local twofold 
axis (Fig. 2b).
In the virus particle, we found that the density of the Fab bound to the dimer related by the 
icosahedral twofold axes of the particle (red-red dimer) was somewhat weaker than that of 
the Fab bound to the dimer sitting at a local twofold axis (cyan-yellow dimer), the density of 
which was comparable to that of the E-protein shell on the particle (Fig. 2d). Because the 
epitopes have the same chemical composition, this indicated that they were not exposed 
identically on the two types of dimers in the particle. The X-ray structure of Fab 747(4)B7 in 
complex with recombinant protein E from DENV-2 to a resolution of 3Å has been 
published, with details of the interactions at the E dimer interface33. That publication also 
describes similar structures of the E protein in complex with three other antibodies from 
both the EDE1 cluster and EDE2 cluster33, which confirms that the antibodies of the two 
subgroups bind in a similar way. The X-ray structures reveal an entirely novel mode of 
binding, with antibodies bridging the E dimer interface distinct from other conformation-
sensitive antibodies34-37.
The EDE overlapped with the FLE, which led us to compare the frequency of mAbs reacting 
to the FLE and those reacting to the EDE in samples from individual patients. We found 
skewed repertoires showing a ‘preference’ for either FLE or EDE (Fig. 3). This 
immunodominance of recognition in a patient was unexpected, as the antibody responses to 
FLE or EDE were polyclonal, which would indicate that the ‘choice’ between the two 
responses in a patient was not simply being driven stochastically by shielding of the epitope 
by whichever of the antibodies to FLE or EDE were the first to bind.
Neutralization potency of mAbs to EDE and FLE
We performed neutralization assays of DENV produced in C6/36 insect cells for three mAbs 
from each of the FLE and EDE groups (Fig. 4). Both mAbs to FLE and mAbs to EDE were 
broadly neutralizing against all four virus serotypes. The EDE2 mAbs (defined as those 
sensitive to glycosylation at Asn153: mAb 747(4)A11 and mAb 747(4)B7) showed lower 
activity against DENV-4, which is related to the fact that the strain we used lacks the glycan 
at position 153. This is a natural variant, but for most DENV-4 strains, glycosylation at this 
position is maintained. These data showed that the EDE defined the binding site for a group 
of antibodies that were broadly reactive across the DENV serocomplex.
Neutralization of DENV produced in insect or mammalian cells
The mAbs to EDE reported here were among the most potent and broadly reactive mAbs to 
DENV, with a 50% neutralization titer (NT50) as low as 3.3 × 10−11 M. During a natural 
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infection with DENV, the host is presented with two forms of the virus: the initial exposure 
is to DENV produced in cells of the insect vector, whereas DENV produced in human cells 
drives subsequent rounds of infection and represents the vast bulk of DENV encountered 
during infection. Viruses produced in these two different types of host cell differ 
antigenically. To examine the neutralization of these two different viral forms, we compared 
neutralization of DENV-2 produced in C6/36 insect cells (C6/36-DENV) with that of virus 
produced in human monocytederived dendritic cells (DCs) (DC-DENV), which are thought 
to be infected after injection of DENV into the skin from the mosquito bite and to be a site 
of DENV replication in the infected human host38.
Of the 83 IB+ mAbs, we mapped 46 to the FLE, and 37 recognized an as-yet-unmapped 
binding site (Supplementary Table 2). None of the 83 IB+ mAbs fully neutralized DC-
DENV, even at high concentration, with only one neutralizing DC-DENV to >80% at a 
concentration of 5 μg/ml (Fig. 5). On the other hand, most of the EDE1 and EDE2 mAbs 
neutralized DC-DENV to >80%, with some reaching 100% neutralization (Fig. 5). IB–3, 
IB-4 and IB–5 mAbs were all poorly neutralizing (Fig. 5). Full binding and neutralization 
curves for representative mAbs demonstrated that mAbs to FLE had diminished binding to 
DC-DENV, as assessed by ELISA, and failed to fully neutralize infection of DCs with 
DENV, whereas the neutralization and binding curves for the mAbs to EDE were more 
closely aligned for C6/36-DENV and DC-DENV (Fig. 6). These data demonstrated the 
superior performance of mAbs to EDE in controlling DENV once infection had become 
established in the mammalian host.
The effect of viral maturation on antibody recognition
The process of DENV maturation described above means that the DENV glycoprotein shell 
contains a series of different compositions and conformations depending on the presence of 
prM in addition to E protein, which is constitutively present in all forms of DENV. To 
assess a series of different forms of DENV, we compared the binding of mAbs to six 
preparations of DENV-2. To assess the degree of prM cleavage, we measured the ratio of 
prM to E protein by ELISA and normalized this to DENV produced in LoVo human colon 
epithelial cells (LoVo-DENV), cells that lack furin activity and produce almost completely 
noninfectious immature viral particles with a full complement of prM17 (Fig. 7a). The viral 
preparations were as follows: C6/36-DENV, which has a relatively high prM content of 
54%; DC-DENV, which has a prM content of 13%; LoVo-DENV, which has a prM content 
approaching 100% (ref. 17); DENV produced in 293T cells overexpressing furin 
(furin-293T-DENV), which has a prM content of 6%; DENV produced in native 293T cells, 
which has a prM content of 63% (293T-DENV); and DENV incubated at pH 5.5, a 
condition in which the E protein irreversibly adopts the trimeric post-fusion conformation 
(acid-DENV)39.
EDE1 and EDE2 mAbs did not bind to LoVo-DENV (Fig. 7b), consistent with the 
observation that at neutral pH, the particles display 60 trimeric spikes and there is no dimer 
to recapitulate an EDE. The mAbs to FLE showed reduced binding to DENV with a low 
content of prM; binding curves for DC-DENV and furin-293T-DENV were shifted 1.5 to 2 
logs to the right of that for C6/36-DENV. Additionally, binding to LoVo-DENV was even 
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more efficient than binding to C6/36-DENV, which emphasized the importance of prM for 
the exposure and efficient binding of antibodies to the fusion loop32,40. These observations 
indicated that prM, which covers the fusion loop of E protein at the top of each spike of 
immature virions, had a weak interaction with E protein, and there was sufficient ‘breathing’ 
such that the mAbs to FLE were able to efficiently displace it from the fusion loop. Such 
‘breathing’ was less important in the context of the mature dimers, which displayed reduced 
binding by the same mAbs. The four IB–4 mAbs, which were isolated from three separate 
patients, bound most efficiently to acid-DENV but showed negligible neutralization (Figs. 5 
and 7b). The mAbs to EDE showed binding to partially processed DENV particles 
(containing more than 60% unprocessed prM, such as C6/36-DENV, 293T-DENV or Vero-
DENV) that was equal to the binding of EDE to nearly fully mature virions, such as DC-
DENV or furin-293T-DENV (Fig. 7b). The ability of mAbs to EDE to neutralize DENV 
produced in both insect cells and DCs indicated their ability to bind to particles with varying 
degrees of maturity containing different amounts of prM.
In a particle that is completely immature, the trimers are totally interlocked, exhibiting more 
extensive intertrimer contacts than intratrimer contacts16,41, consistent with the finding that 
mAbs to EDE, which required an E dimer to bind, did not react with LoVo-DENV. 
However, mAbs to EDE reacted as efficiently with particles that had more than 60% 
unprocessed prM as they did with totally mature virions of DC-DENV or furin-293T-DENV 
with exclusively E dimers at their surface (Fig. 7b). At first glance, this might seem odd, as 
several reports have described the presence of spiky patches of immature lattice (based on E 
protein–prM trimers) next to patches of dimers with a smooth appearance on such particles. 
If these patches were stable, binding of mAbs to EDE should be confined to the mature 
patch only, and overall binding should be reduced.
However, in contrast to the completely immature particles, the trimeric spikes at the edges 
of partially mature patches would not be stabilized by three surrounding trimers and would 
instead be in contact with an adjacent lattice of dimers. EM tomographic reconstruction of 
hybrid particles containing a smooth area of dimer adjacent to a spiky area of trimer has 
shown that the boundary between the two, which is about one icosahedral unit in diameter, 
is not well resolved. It has been proposed that in this area trimer dissociates and dimer is 
formed, and vice versa16,41. Our binding results also indicated that trimers with such a 
boundary were unstable, and they must exhibit a highly dynamic activity, with their subunits 
dissociating and reassociating, alternating between dimers and trimers. These data indicate 
that antibodies to EDE can bind by conformational selection42, stabilizing the dimers when 
they form and displacing prM, which binds at the same site as the mAb to EDE33.
ADE by mAbs to DENV
ADE of DENV infection is one of the mechanisms postulated to increase the severity of 
disease upon secondary infection6. Antibodies formed in response to the primary infection 
are proposed to opsonize but not fully neutralize virus and promote Fc receptor–mediated 
uptake into myeloid cells, driving higher viral loads during secondary infection. ADE can be 
found at subneutralizing concentrations of almost all antibodies, and its perceived risk 
complicates strategies for vaccines against DENV. We assessed the ability of the mAbs to 
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enhance DENV infection of U937 human histiocytic lymphoma monocytes expressing Fc 
receptor. All mAbs tested caused ADE, but it was approximately four-to eightfold lower for 
the EDE group than for the FLE group; the median peak enhancement for the FLE group 
versus the EDE group was 3,745 to 545 on C6/36-DENV and 2,070 to 480 on DC-DENV 
(Fig. 8a). These data indicated that mAbs to EDE were less enhancing than mAbs to the 
fusion loop and that the performance of the mAbs to EDE would be best illustrated by the 
reporting of neutralization as a 90% neutralization titer (NT90) (Fig. 8b).
DISCUSSION
Our analysis here of the human antibody response after natural DENV infection has 
identified a new epitope for mAbs to DENV that was highly conserved and cross-reacted 
across virus serotypes with neutralization titers in the low picomolar range. EDE1 and EDE2 
mAbs efficiently neutralized virus produced in both insect cells and primary human cells; 
these results highlight a previously described weakness of classic FLE-specific mAbs. mAbs 
to FLE, although highly serotype cross-reactive, were unable to fully neutralize virus 
produced in primary human cells. Antibodies to EDE have been shown to bind to the two 
polypeptide subunits of the E protein organized as the basic head-to-tail dimers of the 
mature virion, with the glycan chains modulating the interaction33.
The immunodominance of recognition in a patient was unexpected. As the epitopes overlap, 
it is possible that the most avid antibody might outcompete other antibodies and undergo 
affinity maturation and hence dominate the response, which would lead to a stochastic 
‘choice’ between FLE and EDE. However, the responses to EDE or FLE were polyclonal in 
patients (with different recombinations of variable, diversity and joining regions), which 
would make this less likely as an explanation. The production of cross-reactive antibodies to 
EDE in the single primary case was interesting, and further studies should determine how 
common the production of antibodies to EDE is during primary infection and also the degree 
and persistence of the EDE response in serum following convalescence.
The differences in the neutralization of DC-produced DENV versus that of insect cell–
produced DENV resulted from differences in the prM content of the DENV particles. Both 
insect cell lines and tumor cell lines (such as Vero) produced virus with higher prM content 
than that of virus produced in primary DCs. Our results have highlighted a dynamic activity 
of the E protein on virions, showing in particular that on partially mature particles there was 
continuous ‘breathing’ between dimers and trimers, because otherwise the antibodies to 
EDE would not bind equally to partially mature viral particles and fully mature viral 
particles.
The relatively high content of prM in DENV produced in insect or Vero cells, which is 
commonly used to determine neutralization titers, might overestimate neutralization 
potential for the vast bulk of virus produced by iterative replication cycles in the infected 
host with a low prM content. This tendency to misestimate could be compounded further by 
the use of NT50 values to assess responses, which overestimate the efficacy of the anti-FLE 
component of the response. NT90 values might therefore better represent protection. 
Furthermore, full delineation of the correlates of protection to DENV infection is an 
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imperative following the results of the Sanofi Pasteur dengue vaccine trial8. We propose that 
the induction of antibodies targeting this cross-reactive EDE would be an important feature 
of any successful vaccine against DENV. Assays that measure the neutralization of DENV 
produced in primary human cells or cells overexpressing furin, together with a measure of 
different components of the response (for example, E protein versus prM, and FLE versus 
EDE) should be developed to design more robust and specific assays that can be used to 
predict true immunological protection after immunization.
Finally, current vaccine strategies use a tetravalent formulation with the aim of raising a 
balanced type-specific response to all four DENV serotypes. The description here of such 
potent and cross-reactive antibodies indicates a way for the development of subunit vaccines 
containing the desired epitope and possibly heterologous prime-boost strategies to 
recapitulate responses seen in natural sequential infections. The discovery of the EDE might 
make the generation of potent and broadly neutralizing antibodies a realistic goal for future 
vaccines and might even allow the possibility of a single universal immunogen.
ONLINE METHODS
Samples
Blood samples were collected from inpatients after written informed consent. The study 
protocol was approved by the Scientific and Ethical Committee of the Hospital for Tropical 
Diseases, the Oxford Tropical Research Ethical Committee and the Riverside Ethics 
Committee in the UK. Laboratory confirmation of DENV infection was determined by RT-
PCR detection of DENV nucleic acid (which also confirmed the infecting serotype), NS1 
antigen lateral flow test or seroconversion in an ELISA of IgM. Disease severity was 
classified according to 1997 World Health Organization criteria. Of the patients enrolled in 
the study, two patients were classified as mildly symptomatic of dengue fever, and five 
patients were classified as severely symptomatic of dengue hemorrhagic fever, with plasma 
leakage and bleeding (Supplementary Table 1). Secondary infection was defined based on 
the ratio of DENV-specific IgM to IgG <1.2 on or after day 6 of illness43. Blood samples for 
B cell sorting were collected during the hospitalization period at time points when the blood 
plasmablast population was apparent. Peripheral blood mononuclear cells were isolated from 
whole blood by Ficoll-Hypaque density-gradient centrifugation and resuspended in 10% 
FCS in RPMI medium, for immediate use.
Cells, reagents and antibodies
The C6/36 cell line (a gift from AFRIMS), derived from the mosquito Aedes albopictus, was 
cultured in Leibovitz L-15 at 28 °C. Vero cells (a gift from AFRIMS), U937 cells, and 293T 
cells or 293T cells transfected to express furin were grown at 37 °C in MEM, RPMI-1640 
medium, and DMEM, respectively. All media were supplemented with 10% heat-inactivated 
fetal bovine serum, 100 units/ml penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine. 
The furin-deficient LoVo cell line (CCL-229; ATCC) was maintained in F-12 medium as 
recommended. Monocyte-derived DCs were prepared as described44.
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Peridinin chlorophyll protein–conjugated anti-human CD3 (345766), peridinin chlorophyll 
protein–conjugated anti-human CD20 (345794), fluorescein isothiocyanate–conjugated anti-
human CD27 (555440) and allophycocyanin-conjugated anti-human CD38 (555462) were 
from BD Pharmingen. Phycoerythrin-conjugated anti-human CD19 (R0808), horseradish 
peroxidase–conjugated anti-human IgG (P0214) and peroxidase-conjugated anti-mouse Ig 
(P0447) were from Dako. Alkaline phosphatase (ALP)-conjugated anti-human IgG (A9544), 
biotin-conjugated anti-human IgG (B1140), Biotin-conjugated anti-human IgM (B1265) and 
ALP-streptavidin (S2890) were from Sigma. Mouse monoclonal anti-DENV E (4G2) and 
anti-DENV prM (1H10) were gifts from AFRIMS, C. Puttikhunt and W. Kasinrerk45. Anti-
DENV NS3 (E1D8) was a gift from E. Harris.
Restriction enzymes, Agel-HF (R3552), SalI-HF (R3138), XhoI (R0146), BsiWI (R0553), 
calf-intestinal ALP (M0290) and T4 DNA ligase (M0202L) were from NEB. Bovine serum 
albumin (BSA, A7030), p-nitrophenylphosphate (PNPP, N2770-50), RPMI1640 (R8758), 
DMEM (D5046) and diaminobenzidine (D5905) were from Sigma. MEM (31095) was from 
Gibco.
Viral stocks
DENV-1 (Hawaii), DENV-2 (16681), DENV-3 (H87) and DENV-4 (H241) (gifts from 
AFRIMS) were grown in C6/36 cells. All of these virus preparations contained substantial 
amounts of partially mature particles, as indicated by their prM content. In addition, 
DENV-2 was propagated in DCs, LoVo cells, 293T cells and 293T cells transfected to 
express furin, and cell-free supernatants were collected and stored at −80 °C. Viral titers 
were determined by a focus-forming assay on Vero cells and results are presented as focus-
forming units per ml (ref. 46).
Generation of DENV-specific human mAbs
DENV-specific human mAbs were generated from activated B cells or plasmablasts20,21. 
Perimpheral blood mononuclear cells were stained with anti-CD3 (345766; BD 
Pharmingen), anti-CD19 (R0808; Dako), anti-CD20 (345794; BD Pharmingen), anti-CD27 
(555440; BD Pharmingen) and anti-CD38 (555462; BD Pharmingen). Activated antibody-
secreting cells were then gated as CD19+, CD3−, CD20lo to CD20−, CD27hi and CD38hi. A 
single antibody-secreting cell was sorted into each well of 96-well PCR plates containing 
RNase inhibitor (N2611; Promega). Plates were centrifuged briefly and frozen on dry ice 
before storage at −80 °C. RT-PCR (210212; Qiagen) and nested PCR (203205; Qiagen) 
were then performed to amplify genes encoding γ-chain, λ-chain and κ-chain with 
‘cocktails’ of primers specific for IgG. Products of PCR analyzing genes encoding heavy 
and light chains were then digested with the appropriate restriction endonuclease(s) and 
were cloned into expression vectors for IgG1 or immunoglobulin κ-chain or λ-chain (gifts 
from H. Wardemann). For the expression of antibodies, plasmids enoding heavy and light 
chains were cotransfected into the 293T cell line by the polyethylenimine method (408727; 
Sigma), and antibody-containing supernatants were harvested for further characterization.
Dejnirattisai et al. Page 11
Nat Immunol. Author manuscript; available in PMC 2015 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Enzyme-linked immunospot assay
Enzyme-linked immunospot plates (MSIPN4510; Millipore) were coated with either 
antibody to human immunoglobulin (H17000; Caltag) or ultraviolet irradiation–inactivated 
DENV-1–DENV-4. Plates were washed with RPMI medium and nonspecific binding was 
blocked by incubation for 1 h with 1% BSA in RPMI medium. Sorted antibody-secreting 
cells were added at 500 cells in wells coated with anti-immunoglobulin and DENV and 
samples were incubated overnight at 37 °C in 5% CO2. Plates were washed and then were 
incubated for 2 h at room temperature with biotinylated antibody to human IgG (B1140; 
Sigma) or IgM (B1265; Sigma), followed by streptavidin-ALP (S2890; Sigma). Reactions 
were developed and spots were counted with an AID Elispot plate reader.
Detection of DENV specificity and serotype cross-reactivity by ELISA
Supernatants of mock-infected (uninfected) cells and cells infected with DENV-1–DENV-4 
were captured separately onto a MAXISORP immuno-plate (442404; NUNC) coated with 
mouse antibody to E protein (4G2). Wells in which DENV was captured were then 
incubated with 1 μg/ml of human mAbs (from our patients), followed by ALP-conjugated 
antibody to human IgG (A9544; Sigma). Reactions were visualized by the addition of PNPP 
substrate and were stopped with NaOH. The absorbance was measured at 405 nm.
ELISA of recombinant soluble DENV E protein
Plates were directly coated with 150 ng recombinant soluble E protein (a gift from A 
Flanagan), and bovine serum albumin (BSA) was used as negative control antigen. Protein-
coated wells were then incubated with 1 μg/ml of human mAbs (from our patients), followed 
by ALP-conjugated antibody to human IgG (A9544; Sigma). PNPP substrate was finally 
added and the absorbance was measured at 405 nM.
Immunoblot analysis
For the analysis, DENV-containing supernatants from C6/36 cells were prepared in 
unheated and nonreducing conditions and were separated by electrophoresis through 12% 
SDS polyacryramide gels and transferred by electroblot onto nitrocellulose membranes 
(RPN 303E; Amersham). Nonspecific binding was then blocked with 5% skimmed milk and 
the membranes were probed with DENV-specific human mAbs (from our patients) followed 
by horseradish peroxidase–conjugated antibody to human IgG (P0214; Sigma). Membranes 
were developed with enhanced chemiluminescence substrate (RPN2106; Amersham).
Antibody epitope mapping with VLP mutants
Full-length prM/E of DENV-1 was cloned into the expression vector pHLsec to generate 
VLP (constructed by A. Flanagan)47. VLP mutants were generated by PCR-based site-
directed mutagenesis48. Mutagenic PCR was performed to substitute selected amino acid 
residues in the E protein with alanine through the use of Pfx DNA polymerase (11708021; 
Invitrogen); if the amino acid was already alanine, it was replaced with glycine. After 
treatment with DpnI (R01765; NEB), PCR products were transformed into Escherichia coli 
strain DH5α. All mutations were confirmed by sequencing (Macrogen). Plasmids were 
transfected into the 293T cell lines by the polyethylenimine method and culture supernatants 
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were harvested for epitope mapping. Not all changes to alanine within the antibody footprint 
will block binding, as the change may be too conservative, the interaction is not strong 
enough or the interaction with a given amino acid may rely on conserved main-chain 
interaction and not with the mutant side chain.
The prM content of each VLP preparation, assessed by the ratio of prM to E protein, was 
representative of partially mature particles similar to infectious virus produced in the 293T 
cell line. To identify epitope-specific antibodies, wild-type and mutant VLPs were captured 
with mouse anti-prM (1H10; a gift from C. Puttikhunt). DENV-specific human antibody to 
E protein (from our patients) was then added at 1–5 μg/ml, followed by ALP-conjugated 
antibody to human IgG (A9544; Sigma). Finally, PNPP substrate was added, the reaction 
stopped by the addition of NaOH and absorbance was measured at 405 nm. The relative 
recognition index was calculated as follows: [absorbance of mutant VLP/absorbance of 
wild-type VLP] (recognized by the test mAb)/[absorbance of mutant VLP/absorbance of 
wild-type VLP] (recognized by a group of four mixed mAbs: 751 C5 (FLE), 751 C10 (non-
FLE), 749(2) A7 (non-FLE) and 753(3) B11 (non-FLE)).
Neutralization and enhancement assays
The neutralization potential of mAbs was determined by the focus reduction neutralization 
test (FRNT), whereby the reduction in the number of infected foci is compared with that in 
the control condition (no antibody). Serially diluted antibody was mixed with virus and was 
incubated for 1 h at 37 °C. The mixtures were then transferred to Vero cells and were 
incubated for 3 d. The focus-forming assay was then carried out with mAb 4G2 to E protein, 
followed by goat anti–mouse immunoglobulin (P0047; Sigma), conjugated to horseradish 
peroxidase. The reaction was visualized by the addition of DAB substrate. The percentage of 
focus reduction was calculated for each antibody dilution. 50% FRNT values were 
determined from graphs of percentage reduction versus concentration of antibodies with the 
probit program from the SPSS package.
For the ADE assay, serially diluted antibody was preincubated with virus for 1 h at 37 °C 
and then transferred to U937 cells (Fc receptor–bearing human monocyte cell lines), 
followed by incubation for 4 d. Supernatants were harvested and were titrated on Vero cells 
by a focus-forming assay. The titers of virus were presented as focus-forming units per ml 
and the ‘increment’ was calculated by comparison to viral titers in the absence of antibody.
DENV-binding ELISA
To determine the binding affinity of antibody to DENV generated from various cell types, 
supernatants of mock-infected cells (no virus) or DENV-2 produced from C6/36 cells, DCs, 
293T cells, 293T cells transfected to express furin or LoVo cells were captured onto plates 
coated with mAb 4G2 and then were incubated with serial dilutions of DENV-specific 
human mAb (from our patients) followed by ALP-conjugated anti–human IgG (A9544; 
Sigma). Reactions were developed by the addition of PNPP substrate and were stopped by 
the addition of NaOH. The absorbance was measured at 405 nm. Antigen loading of the 
various viral forms and interday variation between experiments in absorbance readings were 
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normalized by a control ELISA with a humanized version of mAb 3H5, which is specific to 
domain III of DENV-2.
The ratio of prM to E protein was measured by capture of virus onto plates coated with mAb 
4G2, and DENV-2 E protein was measured by ELISA with mAb 3H5 (specific for DENV-2 
domain III). The ratio was calculated as absorbance for prM / absorbance for E protein. 
Percent cleavage of prM was then calculated with reference to virus produced in LoVo cells, 
which was assumed to be 100% uncleaved.
Acid-treated virus
The method has been described49. Culture medium from DENV-2-infected C6/36 cells was 
precipitated with PEG, and viral pellets were resuspended with TNE buffer (12 mM Tris, 
120 mM NaCl and 1 mM EDTA, pH 8.0). Virus was then acidified by the addition of a 
buffer of 0.05 M MES and 0.1 M NaCl to achieve a pH of 5.5. After incubation for 10 min 
at 37 °C, the virus was adjusted back to a pH of 8.0 by the addition of a buffer of 0.1 M 
diethanolamine and 0.1 M NaCl.
Cryo-EM reconstruction
Virus preparation—C6/36 cells were cultured at 32 °C in the presence of 5% CO2. 
During cell passaging, we scraped cells from the dish, avoiding exposure of cells to trypsin. 
Thirty-five Corning tissue-culture treated culture dishes (D × H, 150 mm × 25 mm), each 
containing C6/36 cells in 30 ml of medium, were infected with DENV-2, New Guinean 
strain. Four days after infection, cell culture medium was collected and was centrifuged for 
30 min in a Beckmann centrifuge (11,000g) to pellet large debris to be discarded. The 
supernatant harvested was centrifuged for 1 h in 26 × 38.5 ml centrifuge tubes in a 
Beckmann centrifuge (141,000g) to collect the virus-containing pellet. The sample was left 
for 2 h at 4 °C and subsequently the centrifuged virus was resuspended in PBS buffer by 
soaking of the pellet in the buffer for 10 min. The resuspended sample was then loaded at 
the top of a sucrose gradient (15% to 50%) and was centrifuged for 2 h at 130,000g 
(Beckman Coulter SW41) at 4 °C. A band was located at about one-third the distance from 
the top of the gradient. The gradient material above the band was removed with a pipette; 
then, the virus-containing band was carefully collected with another pipette, or the band was 
directly collected via a syringe. The collected viral sample (1 ml) was diluted to a volume of 
~12 ml with PBS buffer and an Amicon Ultra filter was used to concentrate the sample. The 
resulting 50 μl of purified virus was ready for cryo-EM.
The Fab fragment of mAb 747(4)B7 was purified by size-exclusion chromatography and 
was concentrated to 2.5 mg/ml in Tris-NaCl buffer (50 mM Tris, pH 8, and 0.5 M NaCl) 
with Vivaspin protein concentrators (10 kDa cutoff).
Electron microscopy—Purified virus was mixed with FabB7 (1:4, vol/vol), aiming to 
reach molecular excess of the Fab. Aliquots of 3 μl of the mixture were placed on glow-
discharged holey carbon grids (Quantifoil Cu R2/2). Grids were blotted for 5 s and were 
flash frozen in liquid ethane with an FEI Vitrobot Mark IV. Grids were transferred to an FEI 
Titan Krios electron microscope operating at 300 kV. Images were recorded by Leginon 
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with a Gatan K2 Summit detector in counting mode on the Titan Krios microscope at a 
nominal magnification of ×29,000 (which yields a pixel size of 1.28Å). Underfocus values 
in the final K2 data set ranged from 0.2 μm to 3.5 μm, and 25 frames of each movie were 
used for later image processing.
Image processing—We manually selected more than 8,000 particles with a box size of 
640 pixels from 1,056 micrographs in the final K2 data set. Contrast transfer function 
parameters were estimated with CTFFIND3 program for finding contrast transfer functions 
in electron micrographs50. We filtered the published DENV-2 cryo-EM map (20 as a starting 
model according to online instructions for the RELION (‘regularized likelihood 
optimization’) computer program for refinement of cryo-EM data51, then we used RELION 
for two-dimensional classification and ‘gold-standard’ Fourier shell correlation–based three-
dimensional auto refine. To boost the computation, we ‘down-sampled’ the original particle 
images to 320 pixels, which resulted in a pixel size of 2.56Å. The final resolution of the map 
is 10.24Å when a cutoff of 0.5 is used and 8.5Å when a cutoff of 0.143 is used 
(Supplementary Fig. 3).
Cryo-EM map interpretation—The 3.5Å cryo-EM of the DENV-2 viral particle (EMDB 
accession code, 5520) was used to interpret the E/M glycoprotein shell of the reconstruction 
of the DENV-2–Fab 747(4)B7 complex. Because the two maps are in the same reference 
frame and have the same icosahedral orientation, they superpose directly. The two maps 
were normalized, and the densities above 4 σ were used for correlation optimization. The 
correlation coefficient, obtained with the program Chimera, was 0.98. An attempt to 
optimize the position and orientation of the particle led to a shift of less than 1 pixel and 0° 
rotation, which indicated that the particle was already at its correlation maximum. Density 
maps were presented with Chimera.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Characterization of human mAbs to DENV. (a) Serotype specificity, assessed by ELISA, 
and reaction of 145 mAbs to DENV E protein, assessed by immunoblot analysis. (b) 
Serotype specificity of IB+ and IB− mAbs. Data are representative of two experiments.
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Figure 2. 
Epitope mapping of anti-DENV. (a) Epitope mapping with a panel of mutant VLPs (full 
results, Supplementary Table 2). Top, positions of substitutions in the domain structure of 
DENV E protein (horizontal stripe at top: DI, domain I; DII, domain II; DIII, domain III), 
including substitutions marking the fusion loop around Trp101 and disrupting the Asn153 
glycosylation motif. Right and left margins, antibody groups (gray horizontal lines 
demarcate groups). (b) Positions of substitutions leading to >90% lower binding, mapped to 
either end of the E dimer (gray and orange circles). This model was based on the DENV-2 E 
dimer structure (PDB accession code 1OAN). (c) Three-dimensional reconstruction of the 
DENV-2 particle in complex with Fab 747(4)B7, calculated to a resolution beyond 10Å 
(Supplementary Fig. 3). The contour level shown corresponds to 2*sigma (the root mean 
square deviation of grid values in the map). The reconstruction is colored to provide radial 
depth (red (inner radii) to yellow green to cyan to blue (outer radii) (key)). Here, the 
projecting constant domain of the Fab is dark blue, the variable domain is cyan-green, the E 
protein shell is green-yellow and internal features (parts of the membrane) are seen in red 
through holes in the glycoprotein shell. Arrows point to the density of Fab 747(4)B7 bound 
to the same E dimer. (d) The density corresponding to Fab 747(4)B7 complex superimposed 
on the 3.5Å cryo-EM reconstruction of the DENV-2 virion24, after subtraction of the E shell 
from the reconstruction of the complex. The three independent E and M proteins in the 
icosahedral asymmetric unit are in red for the subunit adjacent to the icosahedral twofold 
axes, are in yellow for that about the threefold axes, and are in cyan for that about the 
fivefold axis. Arrows point to the same density as in c. (e) A single E dimer showing Fab 
binding at the dimer interface matching the cluster of residues sensitive to binding, as 
determined by alanine scanning on DENV-2 VLPs in b.
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Figure 3. 
mAbs to FLE versus mAbs to EDE in individual patients. Distribution of the responses to 
FLE and EDE (as percentages) by seven patients infected with DENV (top, patient 
identification numbers); numbers in centers indicate the number of antibodies from each 
patient. One copy of three duplicate antibodies (one EDE1 mAb and two EDE2 mAbs) from 
patient 752 with identical amino acid sequences was excluded from this and all other 
analyses.
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Figure 4. 
Antibodies to EDE are potent and highly crossreactive in neutralization assays. 
Neutralization assays on Vero cells for nine representative mAbs (identifiers above plots) to 
FLE, EDE1 and EDE2 (top) of all four DENV serotypes (key) produced in C6/36 insect 
cells, presented as the 50% focus reduction neutralization titer (FRNT). Data are from two 
or three independent experiments, each with duplicate wells (mean ± s.e.m.).
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Figure 5. 
EDE-specific antibodies have superior neutralizing activities. Neutralization of C6/36-
DENV (a) or DC-DENV (b) by 138 mAbs (7 mAbs excluded because they did not react to 
DENV-2) at a final concentration of 0.05, 0.5 or 5 μg/ml (key (FRNT)), with Vero cells as 
the target. Below, classification of antibodies as FLE, EDE (five subgroups based on the 
results of VLP mapping: EDE1, EDE2, IB–3, IB–4 and IB–5) or non-FLE (IB+ antibodies 
that failed to map on the VLP); arrows indicate mAbs to EDE used elsewhere33. Data 
represent two independent experiments each with duplicate wells.
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Figure 6. 
Binding and neutralization of virus generated by insect cells and DCs. Titration curves for 
binding, measured by capture ELISA, and neutralization of DC-DENV and C6/36-DENV by 
three mAbs each from the FLE and EDE1 and EDE2 groups (presented as 50% FRNT 
values). AU, arbitrary units. Data are from two independent experiments representative of 
nine experiments each with anti-FLE and anti-EDE1 and seven experiments with anti-EDE2 
(mean ± s.e.m.).
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Figure 7. 
Binding of antibody to viral particles in various states of maturation. (a) ELISA of anti-prM 
and anti–E protein, to calculate a ratio of prM to E protein on viral particles from various 
cells (horizontal axis); results are presented relative to those of virus from LoVo cells, set as 
100% (prM content). Each new batch of virus was tested, and the data were pooled (batches 
of viral preparations tested: 12 (C6/36), 21 (DC), 6 (293T), 5 (293T furin), 8 (LoVo) and 8 
(Vero)). *P = 0.0084 and **P = 0.0005 (one-way analysis of variance (ANOVA), Kruskal-
Wallis test). (b) Capture ELISA of the binding of mAbs to DENV-2 produced from C6/36, 
DC, 293T cells, furin-transfected 293T cells, LoVo cells or acid-treated DENV-2. Data are 
representative of two experiments with three mAbs to FLE, three EDE1 mAbs and three 
EDE2 mAbs, representative of eight mAbs to FLE, ten EDE1 mAbs and eight EDE2 mAbs 
(mean ± s.e.m.).
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Figure 8. 
Reduced ADE with mAbs to EDE. (a) ADE assays on U937 cells infected with DENV-2 
grown in either C6/36 cells or DCs, in the presence of titrations of mAbs to E protein that 
react to FLE or EDE; results are presented as median peak enhancement (fold). *P < 0.0001 
(Mann-Whitney test). (b) NT50 and NT90 values for mAbs to FLE and EDE of C6/36-
DENV and DC-DENV. Each symbol represents an individual mAb (black symbols, this 
study; gray symbols, from ref. 33: diamonds, mAb 752-2C8; triangles, mAb 753(3)C10; 
circles, mAb 747(4)A11; squares, 747(4)B7); small horizontal lines indicate the mean. Data 
are representative of two experiments.
Dejnirattisai et al. Page 26
Nat Immunol. Author manuscript; available in PMC 2015 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
